Involvement of microRNA-181b in the gemcitabine resistance of pancreatic cancer cells

Daisuke Takiuchi, Hidetoshi Eguchi, Hiroaki Nagano, Yoshifumi Iwagami, Yoshito Tomimaru, Hiroshi Wada, Koichi Kawamoto, Shogo Kobayashi, Shigeru Marubashi, Masahiro Tanemura, Masaki Mori, Yuichiro Doki

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background/objectives: MicroRNAs (miRs) have been shown to regulate the sensitivity to several chemotherapeutic agents in various types of cancers. MiR-181b is one of such regulators, yet its importance in pancreatic cancer is not determined so far. The aim of this study was to investigate the relationship between microRNA (miR)-181b expression and gemcitabine resistance in pancreatic cancer cells. Methods: The effects of overexpression or knockdown of miR-181b on four pancreatic cancer cell lines exposed to gemcitabine were examined. The induction of apoptosis and the changes of the cylindromatosis (CYLD) protein were examined. Furthermore, the effect of small interference RNA for CYLD (siCYLD) on cell viability and the relationship between CYLD and nuclear factor kappa B (NF-kB) were investigated. Results: The expression of miR-181b was higher in BxPC3, Panc1 and PSN1 cells compared with MiaPaCa2 cells. Pre-miR-181b transfection into MiaPaCa2 cells increased their gemcitabine resistance, whereas anti-miR-181b transfection into the other pancreatic cancer cell lines reduced their resistance to gemcitabine and led to the induction of apoptosis. The protein levels of CYLD were increased by anti-miR- 181b in Panc1 and PSN1 cells. Inhibition of CYLD increased the NF-kB activity and gemcitabine resistance in Panc1 and PSN1 cells. Conclusions: The present study demonstrated that miR-181b was associated with the resistance of pancreatic cancer cells to gemcitabine, and verified that miR-181b enhances the activity of NF-kB by inhibiting CYLD, leading to the resistance to gemcitabine. Our results suggest that miR-181b is a potential target for decreasing gemcitabine resistance.

Original languageEnglish
Pages (from-to)517-523
Number of pages7
JournalPancreatology
Volume13
Issue number5
DOIs
Publication statusPublished - Jan 1 2013
Externally publishedYes

Fingerprint

gemcitabine
MicroRNAs
Pancreatic Neoplasms
NF-kappa B
Transfection
Apoptosis
Cell Line

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

Takiuchi, D., Eguchi, H., Nagano, H., Iwagami, Y., Tomimaru, Y., Wada, H., ... Doki, Y. (2013). Involvement of microRNA-181b in the gemcitabine resistance of pancreatic cancer cells. Pancreatology, 13(5), 517-523. https://doi.org/10.1016/j.pan.2013.06.007

Involvement of microRNA-181b in the gemcitabine resistance of pancreatic cancer cells. / Takiuchi, Daisuke; Eguchi, Hidetoshi; Nagano, Hiroaki; Iwagami, Yoshifumi; Tomimaru, Yoshito; Wada, Hiroshi; Kawamoto, Koichi; Kobayashi, Shogo; Marubashi, Shigeru; Tanemura, Masahiro; Mori, Masaki; Doki, Yuichiro.

In: Pancreatology, Vol. 13, No. 5, 01.01.2013, p. 517-523.

Research output: Contribution to journalArticle

Takiuchi, D, Eguchi, H, Nagano, H, Iwagami, Y, Tomimaru, Y, Wada, H, Kawamoto, K, Kobayashi, S, Marubashi, S, Tanemura, M, Mori, M & Doki, Y 2013, 'Involvement of microRNA-181b in the gemcitabine resistance of pancreatic cancer cells', Pancreatology, vol. 13, no. 5, pp. 517-523. https://doi.org/10.1016/j.pan.2013.06.007
Takiuchi D, Eguchi H, Nagano H, Iwagami Y, Tomimaru Y, Wada H et al. Involvement of microRNA-181b in the gemcitabine resistance of pancreatic cancer cells. Pancreatology. 2013 Jan 1;13(5):517-523. https://doi.org/10.1016/j.pan.2013.06.007
Takiuchi, Daisuke ; Eguchi, Hidetoshi ; Nagano, Hiroaki ; Iwagami, Yoshifumi ; Tomimaru, Yoshito ; Wada, Hiroshi ; Kawamoto, Koichi ; Kobayashi, Shogo ; Marubashi, Shigeru ; Tanemura, Masahiro ; Mori, Masaki ; Doki, Yuichiro. / Involvement of microRNA-181b in the gemcitabine resistance of pancreatic cancer cells. In: Pancreatology. 2013 ; Vol. 13, No. 5. pp. 517-523.
@article{0c472c17cf41473cbfb2f3741aa73918,
title = "Involvement of microRNA-181b in the gemcitabine resistance of pancreatic cancer cells",
abstract = "Background/objectives: MicroRNAs (miRs) have been shown to regulate the sensitivity to several chemotherapeutic agents in various types of cancers. MiR-181b is one of such regulators, yet its importance in pancreatic cancer is not determined so far. The aim of this study was to investigate the relationship between microRNA (miR)-181b expression and gemcitabine resistance in pancreatic cancer cells. Methods: The effects of overexpression or knockdown of miR-181b on four pancreatic cancer cell lines exposed to gemcitabine were examined. The induction of apoptosis and the changes of the cylindromatosis (CYLD) protein were examined. Furthermore, the effect of small interference RNA for CYLD (siCYLD) on cell viability and the relationship between CYLD and nuclear factor kappa B (NF-kB) were investigated. Results: The expression of miR-181b was higher in BxPC3, Panc1 and PSN1 cells compared with MiaPaCa2 cells. Pre-miR-181b transfection into MiaPaCa2 cells increased their gemcitabine resistance, whereas anti-miR-181b transfection into the other pancreatic cancer cell lines reduced their resistance to gemcitabine and led to the induction of apoptosis. The protein levels of CYLD were increased by anti-miR- 181b in Panc1 and PSN1 cells. Inhibition of CYLD increased the NF-kB activity and gemcitabine resistance in Panc1 and PSN1 cells. Conclusions: The present study demonstrated that miR-181b was associated with the resistance of pancreatic cancer cells to gemcitabine, and verified that miR-181b enhances the activity of NF-kB by inhibiting CYLD, leading to the resistance to gemcitabine. Our results suggest that miR-181b is a potential target for decreasing gemcitabine resistance.",
author = "Daisuke Takiuchi and Hidetoshi Eguchi and Hiroaki Nagano and Yoshifumi Iwagami and Yoshito Tomimaru and Hiroshi Wada and Koichi Kawamoto and Shogo Kobayashi and Shigeru Marubashi and Masahiro Tanemura and Masaki Mori and Yuichiro Doki",
year = "2013",
month = "1",
day = "1",
doi = "10.1016/j.pan.2013.06.007",
language = "English",
volume = "13",
pages = "517--523",
journal = "Pancreatology",
issn = "1424-3903",
publisher = "S. Karger AG",
number = "5",

}

TY - JOUR

T1 - Involvement of microRNA-181b in the gemcitabine resistance of pancreatic cancer cells

AU - Takiuchi, Daisuke

AU - Eguchi, Hidetoshi

AU - Nagano, Hiroaki

AU - Iwagami, Yoshifumi

AU - Tomimaru, Yoshito

AU - Wada, Hiroshi

AU - Kawamoto, Koichi

AU - Kobayashi, Shogo

AU - Marubashi, Shigeru

AU - Tanemura, Masahiro

AU - Mori, Masaki

AU - Doki, Yuichiro

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Background/objectives: MicroRNAs (miRs) have been shown to regulate the sensitivity to several chemotherapeutic agents in various types of cancers. MiR-181b is one of such regulators, yet its importance in pancreatic cancer is not determined so far. The aim of this study was to investigate the relationship between microRNA (miR)-181b expression and gemcitabine resistance in pancreatic cancer cells. Methods: The effects of overexpression or knockdown of miR-181b on four pancreatic cancer cell lines exposed to gemcitabine were examined. The induction of apoptosis and the changes of the cylindromatosis (CYLD) protein were examined. Furthermore, the effect of small interference RNA for CYLD (siCYLD) on cell viability and the relationship between CYLD and nuclear factor kappa B (NF-kB) were investigated. Results: The expression of miR-181b was higher in BxPC3, Panc1 and PSN1 cells compared with MiaPaCa2 cells. Pre-miR-181b transfection into MiaPaCa2 cells increased their gemcitabine resistance, whereas anti-miR-181b transfection into the other pancreatic cancer cell lines reduced their resistance to gemcitabine and led to the induction of apoptosis. The protein levels of CYLD were increased by anti-miR- 181b in Panc1 and PSN1 cells. Inhibition of CYLD increased the NF-kB activity and gemcitabine resistance in Panc1 and PSN1 cells. Conclusions: The present study demonstrated that miR-181b was associated with the resistance of pancreatic cancer cells to gemcitabine, and verified that miR-181b enhances the activity of NF-kB by inhibiting CYLD, leading to the resistance to gemcitabine. Our results suggest that miR-181b is a potential target for decreasing gemcitabine resistance.

AB - Background/objectives: MicroRNAs (miRs) have been shown to regulate the sensitivity to several chemotherapeutic agents in various types of cancers. MiR-181b is one of such regulators, yet its importance in pancreatic cancer is not determined so far. The aim of this study was to investigate the relationship between microRNA (miR)-181b expression and gemcitabine resistance in pancreatic cancer cells. Methods: The effects of overexpression or knockdown of miR-181b on four pancreatic cancer cell lines exposed to gemcitabine were examined. The induction of apoptosis and the changes of the cylindromatosis (CYLD) protein were examined. Furthermore, the effect of small interference RNA for CYLD (siCYLD) on cell viability and the relationship between CYLD and nuclear factor kappa B (NF-kB) were investigated. Results: The expression of miR-181b was higher in BxPC3, Panc1 and PSN1 cells compared with MiaPaCa2 cells. Pre-miR-181b transfection into MiaPaCa2 cells increased their gemcitabine resistance, whereas anti-miR-181b transfection into the other pancreatic cancer cell lines reduced their resistance to gemcitabine and led to the induction of apoptosis. The protein levels of CYLD were increased by anti-miR- 181b in Panc1 and PSN1 cells. Inhibition of CYLD increased the NF-kB activity and gemcitabine resistance in Panc1 and PSN1 cells. Conclusions: The present study demonstrated that miR-181b was associated with the resistance of pancreatic cancer cells to gemcitabine, and verified that miR-181b enhances the activity of NF-kB by inhibiting CYLD, leading to the resistance to gemcitabine. Our results suggest that miR-181b is a potential target for decreasing gemcitabine resistance.

UR - http://www.scopus.com/inward/record.url?scp=84892583351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892583351&partnerID=8YFLogxK

U2 - 10.1016/j.pan.2013.06.007

DO - 10.1016/j.pan.2013.06.007

M3 - Article

C2 - 24075517

AN - SCOPUS:84892583351

VL - 13

SP - 517

EP - 523

JO - Pancreatology

JF - Pancreatology

SN - 1424-3903

IS - 5

ER -